Salarius Pharmaceuticals Inc
SLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.92M
Close$
$2.30
173.8% upside
Current Fair Value
173.8% upsideUndervalued by 173.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.92 Million |
|---|---|
| Enterprise Value | $329,203.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-25.99 |
| Beta | 0.32 |
| Outstanding Shares | 481,587 |
Return
| Return on Equity | -336.14% |
|---|---|
| Return on Assets | -154.73% |
| Return on Invested Capital | -340.13% |
Valuation & Multiples
| P/E Ratio | -0.33 |
|---|---|
| PEG | -1.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.02 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 9.8 |
| Debt to Equity | 0.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 14, 2025
EPS Estimate
$-33.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.46%▲ 16.34% |
|---|---|
| Total Invested | $51,429▲ 2501.37% |
| Investors Holding | 9▲ 4.00% |
ESG Score
No data
About Salarius Pharmaceuticals Inc
CEO: David Arthur